Levocetirizine dihydrochloride

Levocetirizine dihydrochloride (CAS 130018-87-0) is the active R-enantiomer of cetirizine, supplied as a dihydrochloride salt. It is recognised under the trade names Xyzal, Xusal, and Xyzall, and carries the development code UCB 28556. No E-code designation applies to this substance.

In pharmaceutical manufacturing, levocetirizine dihydrochloride serves as the active pharmaceutical ingredient in second-generation antihistamine formulations, selectively blocking peripheral H1 receptors to suppress allergic response. In personal care formulations, it is evaluated for antimicrobial and preservation activity, functioning by disrupting microbial membrane integrity at low concentrations.

The substance is sourced to pharmaceutical-grade standards aligned with Ph.Eur. monograph requirements and is subject to REACH registration within the EU. It is available as a fine powder in quantities suited to both development-scale and commercial production. Procurement teams should confirm grade specification and documentation requirements, including CoA and GMP compliance, prior to ordering.